Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilazodone Fixed-dose Study in Major Depressive Disorder
NCT01473394Phase 4Completed
- Sponsor
- Forest Laboratories
- Start
- Dec 2011
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in major depressive disorder (MDD) comparing Placebo with Vilazodone (2 arms). Primary endpoint: Change From Baseline in the Montgomery-Åsberg Depression Rating Scale Total Score at 8 weeks. Started Dec 2011; status: completed.
02
Drugs
vilazodone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01473394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01473394.